Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : VLP-N-00023
| Cat. No. | VLP-N-00023 |
| Description | Virus-Like Particles that contain structurally intact Human Claudin-18.2 protein, designed for antibody screening and ligand binding assays etc. |
| Gene Abbr | CLDN18-A2 |
| Applications | Human CLDN18-A2 virus-like particles (VLPs) have potential in a variety of biomedical applications, particularly in the areas of immunotherapy and vaccine development. Here are some possible applications: Cancer immunotherapy: VLPs presenting the CLDN18-A2 epitope could be used to create targeted therapies that help the immune system recognize and attack cancer cells that express this marker. Monoclonal antibodies against CLDN18.2 could be developed for the treatment of CLDN18.2-positive tumors. VLPs could help design and test these antibodies. Vaccine development: VLPs could be used as a platform for the development of therapeutic cancer vaccines. The idea is to present the CLDN18-A2 epitope on the VLP to the immune system, thereby training it to recognize and destroy cancer cells that express CLDN18.2. Biomarker identification: VLPs containing the CLDN18-A2 epitope could be used to develop diagnostic assays to identify the presence of tumors that express this protein. For example, labeled VLPs could potentially be used in imaging techniques to detect cancer cells. Screening platforms: They can be used as a tool to screen compounds that interact with or inhibit CLDN18.2, aiding in the discovery of new drugs. Drug delivery systems: VLPs can be designed to deliver therapeutic agents directly to cancer cells expressing CLDN18.2, thereby increasing specificity and reducing side effects of treatment. |
| Storage | -80˚C |
| Shipping | Dry ice |
Claudin-18.2 (CLDN18-A2) is a member of the claudin family, a group of integral membrane proteins that are essential for the formation and function of tight junctions in epithelial and endothelial cell layers. These tight junctions play a crucial role in maintaining tissue integrity by regulating the passage of ions, molecules, and water between cells. CLDN18-A2 is primarily expressed in gastric epithelial cells, where it participates in the maintenance of tight junctions that are essential for the barrier function of the gastric wall. This protein has attracted considerable attention in cancer research due to its restricted expression pattern and its role in various malignancies, especially gastric cancer. Advances in molecular biology and immunohistochemistry have shown that CLDN18-A2 is overexpressed in several gastrointestinal cancers, including gastric adenocarcinoma and pancreatic cancer, making it a promising target for therapeutic intervention.
Human CLDN18-A2 virus-like particles (VLPs) represent a cutting-edge advance in the field of immunotherapy and vaccine development. VLPs are molecular mimics of viruses that provide an effective platform for presenting antigens to the immune system, resulting in a potent immunogenic response. Structurally intact human Claudin-18.2 VLPs are designed to present the CLDN18-A2 protein in its native conformation, retaining the structural and functional integrity necessary to elicit an appropriate immune response. These VLPs lack viral genetic material, ensuring they are non-infectious and safe. They mimic the external morphology of the natural virus, thereby effectively stimulating the host's immune system without the risk of actual viral infection.
A: We offer CLDN18-A2 virus-like particles (VLPs) that have undergone morphological and compositional analysis: Validation includes the use of electron microscopy and other imaging techniques to ensure that the VLPs have the desired structure, size and morphology. In addition, immunogenicity assessments, safety assessments, and evaluations were passed, all showing good quality and efficacy. You can use them with confidence.
A: Human CLDN18-A2 VLP products have various applications. They can be used in research laboratories to study the interaction between CLDN18-A2 and host cells. Furthermore, these VLPs can be utilized in diagnostic tests to detect the presence of CLDN18-A2 antibodies or antigens in patient samples. Additionally, as a potential therapeutic tool, Human CLDN18-A2 VLP products may be explored for the development of vaccines or targeted drug delivery systems.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
I procured the Human CLDN18-A2 Virus-Like Particles for our laboratory and I am extremely pleased with the product. The particles were user-friendly and exhibited outstanding stability during our experiments. The instructions provided were concise and useful. Moreover, the customer service team was highly responsive and offered prompt assistance. Overall, an excellent acquisition!
I have been using the Human CLDN18-A2 Virus-Like Particles for my research project and they have exceeded my expectations. The quality of the particles is superb and they have been very reliable in my experiments. The pricing is also very competitive compared to other similar products on the market. I am very satisfied with this purchase and will continue to purchase.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.